Background. Breast cancer (BC) is the second most common cause of brain metastases (BM). Optimal management of BM from BC is still debated. In an attempt to provide appropriate treatment and to assist with optimal patient selection, several specific prognostic classifications for BM from BC have been established. We evaluated the prognostic value and validity of the 6 proposed scoring systems in an independent population of BC patients with BM.
Breast cancer (BC) is the most prevalent neoplasm in adult women with more than 209 000 new diagnoses in the United States and 50 000 new cases per year in France. 1 Improvements in systemic therapy have increased the overall survival of BC patients, including metastatic patients. 2 In the context of controlled systemic disease, the prevalence of brain metastases (BM) from BC is increasing. 3 BC is the second leading cause of BM after lung cancer and accounts for 17% -20% of all cases. 4, 5 Median survival after BM onset depends on many factors related to patient characteristics, disease status, and treatment modalities. 6 -8 BM treatment options currently include whole-brain radiotherapy (WBRT), surgery, stereotactic radiosurgery (SRS), or a combination of these methods. Recently, a growing body of evidence indicates that systemic therapies may have antitumor activity at the central nervous system level. 9 However, the optimal management of BM is still debated.
In an attempt to provide appropriate treatment and to assist with optimal patient selection, several prognostic classifications for BM have been established, 10 -15 which were mainly based on patients with non-small cell lung cancer (52.4% -77% of cases). More recently, based on the assumption that the prognosis of patients with newly diagnosed BM would differ depending on the primary site, 16 many authors have described independent prognostic factors in the particular setting of BMBC, and 6 prognostic classifications for this patient subgroup have been proposed. 10 -15 However, these scoring systems were not validated with an independent population, and they have not been compared with each other in the same population.
The aim of our study was to evaluate the prognostic value and validity of these 6 scoring system in an independent BC population with newly diagnosed BM who were referred to our institution for treatment.
Materials and Methods
We conducted a retrospective monocentric analysis using the medical records of patients newly diagnosed with BM from BC between October 1995 and July 2011. Patients with leptomeningeal disease synchronous with or before BM diagnosis were excluded. This study was approved by our local ethics committee and complies with the principles of the Declaration of Helsinki.
All patients had histologically proven breast carcinoma. BM was diagnosed or confirmed through brain magnetic resonance imaging (MRI) with or without pathological confirmation.
Treatment modalities included WBRT, surgical resection, SRS, and systemic treatment (such as chemotherapy, endocrine therapy, and targeted therapy). BM treatment consisted of these modalities alone or in combination.
We extracted the following data from the patients' charts when available: age (,60 years old or .60 years old), Karnofsky performance status (KPS) at the time of BM diagnosis, number of BM, hormonal receptor status (estrogen receptor [ER] and progesterone receptor [PR]), human epidermal growth factor receptor 2 (HER2) expression profile in the primary tumor, tumor subtype, presence of extracranial metastases (ECM), BM as the first recurrence site (not exclusive of concomitant systemic site), BM treatment modalities, interval between initial diagnosis of BC and diagnosis of BM (,40 months or .40 months), interval between first diagnosis of metastasis and diagnosis of BM (,11.5 months or .11.5 months), and lymphocyte count. Lymphopenia was defined as ,0.7 G/l on blood count at BM diagnosis. Controlled systemic disease was defined as no progressive disease on 2 subsequent evaluations that were 3 months apart. Immunohistochemistry (IHC) was carried out for the evaluation of ER, PR, and HER2 expression. Fluorescence in situ hybridization (FISH) analysis for HER2 amplification was carried out for an IHC score of 2+. Tumor subtype may be approximated as follows: basal (triple negative 12 or HER2/ER/PR negative), luminal A (HER2 negative, ER/PR positive), luminal B (HER2/ER/PR positive), and HER2 (HER2 positive, ER/PR negative). Absence of extracerebral disease was defined as complete remission of initial BC and absence of metastatic sites other than BM.
Each of the 6 prognostic scores proposed for BM from BC was applied to this population, provided that all prognostic factors required for its assignation were available (Supplementary data, Table 1 ), leading to a different sample size for each model. Overall survival (OS) was defined as the time from BM diagnosis to death from any cause, censored at the date of last contact. The date of BM diagnosis was defined as the day when BM was confirmed by imaging or by pathological examination of resected specimens.
OS was estimated by the Kaplan-Meier product limit method. The log-rank test was used to compare survival rates by univariate analysis. Prognostic factors with P , .15 in univariate analysis were explored by multivariate analysis. Cox proportional hazards models were used for multivariate analyses and to estimate hazard ratios in regression models. Multivariate analyses were restricted to the subset of patients (140 of 152) with all the aforementioned prognostic factors available. Reported P-values were 2-sided, and P , .05 was considered statistically significant.
The scores' predictive values were estimated by the C-index and the Brier score. The C-index (Harrell's concordance index) was used to estimate the discriminative ability and the concordance with the final multivariate model. Brier scores measured the mean square error of each score class, while Brier relative error reduction measured the improvement, by the scoring system evaluated, of the predictions relative to a model that gave all women the same outcome probability. In order to evaluate scoring system accuracy, positive predictive values (PPV) of the worst and best classes were analyzed. PPV was defined as the proportion of patients in the worst prognostic group with an OS less than 3.5 months (first quartile of OS) and the proportion of patients in the best prognostic group with an OS more than median OS (14.0 months). Statistical analyses were performed with SPSS version 17 (SPSS Inc., Chicago) and R version 2.15.2. 17 
Results

Population Characteristics
During the study period, 152 consecutive patients with newly diagnosed BM from BC were referred to our institution for treatment.
The median times from initial diagnosis to BM occurrence was significantly longer (P , .001) for patients with luminal A subtype (65.8 months; 95% CI, 51.4-80.1) than for luminal B subtype (41.3 months; 95% CI, 30.5-52.0), HER2 subtype (29.2 months; 95% CI, 13.2 -45.2), and TN subtype (30.5 months; 95% CI, 22.7-38.4). BM was the first metastatic site for 28% of patients (37% of patients with TN status and 22% of HER2-positive patients).
At BM diagnosis, 27% of patients presented with altered general status (KPS , 70). The majority of them had multiple cerebral metastases with uncontrolled systemic disease. Few patients presented with only a cerebral metastatic site (12.6%), and only 3 patients (2%) had synchronous BM at the initial diagnosis.
The majority of patients underwent radiotherapy or combined local treatments with adjunct systemic treatment. Among HER2-positive patients, 60% received an anti-HER2 therapy (trastuzumab, n ¼ 27; lapatinib, n ¼ 7) after BM diagnosis. In HR-positive patients, 51% received hormonal therapy after the onset of BM.
Patient Outcomes
Thirty-one patients (20.4%) were alive at the last follow-up with a median follow-up since BM onset of 30.2 months (range, 2.2-81.8 months). Median OS (MOS) and 1-and 2-year survival rates since BM diagnosis were 14.0 months (95% CI, 10.8-17.2), 53%, and 25%, respectively.
Prognostic Scores
Repartition of patients into prognostic classes of the 6-scoring system is shown in Table 2 . Some classes were poorly represented in certain classifications; for example, there were only 2 patients in Park class 4 and 1 in Niwinska class 1. Analyses of the 6 breast prognostic scores are reported in Table 2 . Sperduto-GPA (P , .001), Nieder (P , .001), Park (P , .001), Niwinska (P , .001), Claude' (P , .001), and Le Scodan' (P ¼ .034) scores all exhibited significant prognostic value for OS. The Kaplan -Meier curves are shown in Figure 1 .
In order to explore the predictive value of each scoring system, we made comparisons with the C-index and the Brier score. The best C-index was found for the Nieder score (0.672), whereas the worst were for the Le Scodan and Claude scores. Relative error reduction analyzed by Brier score was maximal for the Nieder' score with an error reduction of 16.3%. Use of the Sperduto' model reduced relative error of only 9.7% in our population. These results suggest the best predictive and prognostic values for the Nieder score (Table 3 ; Supplementary data, Figure 1 ).
PPVs were approached for the 6 models. The Nieder' score produced the best PPV at 71%, while the Sperduto score PPV was 69% (Supplementary data, Figure 1 ).
Prognostic Factors (Table 4 and Figure 2)
In univariate analysis, patients .60 years (P ¼ .015); KPS , 70, (P , .001), radiotherapy alone (P , .001), absence of systemic Tabouret et al.: Prognostic score for brain metastases therapy (P , .001), absence of anti-HER2 therapy for HER2-positive subtype (P , .010), absence of hormonotherapy for ER/PR positive patients (P ¼ .002), lymphopenia (P ¼ .022), and BM as the first metastatic site (P ¼ .022) were significantly associated with decreased OS. Shorter interval between primary and BM diagnosis (P ¼ .079), systemic disease status (P ¼ .070), and number of BMs (P ¼ .074) tended to be significant. No prognostic value was found for subtype of BC (P ¼ .420); hormonal receptor (0.760), HER2 (P ¼ .152), or TN status (P ¼ .545); or interval between first metastatic event diagnosis and BM diagnosis (P ¼ .665).
MOS of TN, luminal A, HER2, and luminal B were 15.1 (95% CI, 5.6 -24.7), 12.3 (95% CI, 9.5-15), 20.2 (95% CI, 17.1 -23.2), and 20.5 months (95% CI, 11.4 -29.5), respectively (Supplementary data, Table 1 ).
In multivariate analysis, independent prognostic predictors for better survival were KPS . 60 (P , .001; HR, 0.292), absence of systemic disease (P , .045; HR, 0.454), interval between initial diagnosis and BM . 40 months (P ¼ .044; HR, 0.637), use of systemic treatment (P , .001; HR, 0.125) and combined local treatment and/or SRS and/or surgery (P ¼ .001; HR, 0.464). Number of BM, BM as first metastatic site, and age did not have prognostic value.
Discussion
The prognosis for BC patients with newly diagnosed BM is highly variable, and median survival (MS) can range from 3 months to over 2 years. 10 Therapeutic decisions closely depend on estimated prognosis. The establishment, as well as validation, of prognostic Previously published prognostic classifications were based on retrospective data and therefore depended on the studied population characteristics and required validation in an independent series.
For the establishment of such classifications, although systemic treatments (particularly anti-HER2 therapies) show proven prognostic value, they should not be included in prognostic factors since they affect patients' outcome after the therapeutic decision, which would be the optimal time to use prognostic scores that support therapeutic choice. Nonetheless, physicians should be aware of the crucial positive impact on survival of anti-HER2 therapies administered after the onset of BM for HER2-positive patients and recognize that omission of this systemic treatment would downgrade this good prognostic factor to a poor one and consequently invalidate the prognostic value of a score that includes HER2 status. The boundary between prognostic factor and predictive factor becomes narrow because HER2 status is a favorable prognostic factor provided that a specific treatment is applied, which is the current standard of care. For the same reasons, HER2-positive patients who do not receive anti-HER2 therapies at the onset of BM (due to unavailability before the anti-HER2 era) should not be included in prognostic factor studies because they bias the results; this is likely the reason why Park et al 13 found that HER2-positive patients have poorer prognoses, which is the opposite of what has been reported by multiple other Tabouret et al.: Prognostic score for brain metastases studies. 18 -20 In our study, anti-HER-2 therapies were available for all HER-2 positive patients at the time of BM diagnosis, and patients who did not receive this treatment were unsuitable for this treatment due to being in generally poor condition.
In our prognostic classification validation study, the 6 prognostic scoring systems 10 -15 were all able to discriminate patients in groups with different survivals, but their discriminative ability and positive and negative predictive values were somewhat different. *Excluded of multivariate analysis because of the lack of patients. Abbreviations: BM, brain metastases; HR, hazard ratio; OS, overall survival; WBRT, whole-brain radiotherapy.
Tabouret et al.: Prognostic score for brain metastases
The classification from Le Scodan et al 14 provided 3 prognostic classes with MOS of 19.5, 12.5, and 3.5 months for classes I, II, and III, respectively. The positive predictive value of this classification was 47%. The main weakness of this prognostic classification is that TN patients always belong to class III regardless of other factors. Twenty-five patients were TN in our study, and their MOS was 15 months, a particularly high MOS for this subtype perhaps biased by small sample sizeonetheless, despite unfavorable, TN subtype in itself is probably not sufficient to predict a poor outcome. Moreover, TN subtype is heterogeneous breast cancer subtype, and not all TN have the outcome of basal tumors, which were frequently associated to TN subtype. This could explain the poor Brier score (reduction of 2.4%).
Using the prognostic classification from Claude et al. 15 based on 2 prognostic factors (KPS and lymphopenia), 2 prognostic groups could be differentiated (poor and good) with 3.2 and 15.7 months MOS, respectively. The positive predictive value was 54% (Supplementary data, Table 2 ), and only 31% of patients who lived less than 4 months were classified in the poor prognostic group. Therefore, the 2 prognostic factors for this classification appear insufficient to determine BMBC patient outcome.
Because only 1 patient belonged to the best prognostic class in the classification described by Niwinska et al, 11 patients in class II were considered to have good prognoses. The MOS of patients assigned to class II was 16.4 months. The positive predictive value was 59%. Patients who belonged to the worse prognostic group had mostly KPS ≤ 50 and were defined as class III; all but 4 of these patients had a survival time less than 3.5 months. This criterion therefore appears a good one to highlight patients with a very poor prognosis, with the goal being to avoid aggressive treatments and perhaps consider the best supportive care. 21, 22 Nonetheless, 73% of patients with poor prognosis had a KPS . 50 at the onset of BM and were therefore misclassified in class II. Despite its relevance, KPS as single prognostic factor for classification appears insufficient to identify patients with poor prognosis.
The patients in the population-based study by Park et al. 13 did not receive any anti-HER2 therapy at the onset of BM, explaining why having HER2-positive status appeared to be an adverse prognostic factor, which is the opposite of all other studies. 7, 23 Moreover, 1 of the 3 independent prognostic factors was systemic treatment-related, making this classification less relevant for therapeutic decision. Indeed, patients assigned to the best prognostic class (class I) had a worse MOS than patients classified in prognostic class II.
The last 2 classifications weighted prognostic factors, with greater importance being given to the KPS. Sperduto et al. 10 investigated 6 prognostic factors (age, KPS, genetic subtype, number of BM, presence of extracranial metastases) and time from primary diagnosis to development of BM (TPDBM), which was found to be correlated with tumor subtype 24 -26 (as we also highlighted). Prognostic factors were weighted relative to the magnitude of their regression coefficients. MOS for patients assigned to classes I, II, III, and IV were 30.0, 20.2, 12.3, and 4.7 months, respectively. The PPV was 69%, which leads to consequent misclassifications. BM treatment modalities applied to our population were close to those applied in the population-based study by Sperduto et al. and could not explain the lack of power of the PPV. The PPV rose only to 70% if we excluded HER2-positive patients who did not undergo anti-HER2 therapies at the onset of BM. This is somewhat disappointing because the authors investigated all possible known prognostic factors. This classification may therefore be refined, perhaps by adjusting weights given to each prognostic factor. It is also possible that using histologic subtypes as a surrogate of genetic subtypes led to inaccurate prognostic subgroups.
In conclusion, the prognostic classification from Nieder et al. 12 had the best C-index and Brier score. The PPV was 71%, which remains insufficient. The superiority of the Nieder' score in the discrimination of patients with newly diagnosed BM from breast cancer could attributed to the prognostic factors included in this score. Indeed, the Nieder' score is one of the few to consider ECM status as an independent prognostic factor, which also demonstrated significant correlation with survival in our multivariate analysis. The Niwinska' score also included ECM status as a prognostic factor but stratified patients less accurately. This was likely due to the highly restrictive criteria assigning patients to classes I and III, so that most patients (89%) were classified in the intermediate group that therefore became highly heterogeneous.
Among the 4 other BCBM scores, 3 did not include ECM status in their prognostic factor analysis. 13 -15 Sperduto et al established a BC-GPA based on a population of more than 800 patients with newly diagnosed BM from breast cancer treated in 11 institutions. 23 They included ECM status in prognostic factors analyzed for survival, but the definition of presence or absence of ECM was lacking. Did all institutions consider the same definition of "absence of ECM"? This definition is crucial, and it could be possible that patients having ECM present but nonprogressive (stable or regressive under treatment) had been classified as without or with ECM according to the investigators. The publication from Sperduto et al does not address this question.
Our results compare favorably with those of Braccini et al., 27 who compared performances of several prognostic indices for BC patients with BM and found that RPA (Recursive Partitioning Analysis) based on KPS, age, and systemic disease status 28 performed better than the new prognostic index developed for BCBM.
Another concern that could contribute to the limited value of these scoring systems is that none of them include the neurologic condition of the patient. However, some authors have already highlighted its impact on survival of patients with BM. 29, 30 The inclusion of this item in prognostic factors analyses should therefore be systematic because it would influence the prognostic classifications arising.
Conclusion
Independent prognostic factors differ among studies, and validation of prognostic scores in independent series is mandatory to establishing a useful tool for treatment decision making and refining prognostic classifications.
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